Practice-Changing Prostate Cancer Data From ASCO Genitourinary Cancers Symposium 2022

Bertrand Tombal, MD, PhD


March 09, 2022

Professor Bertrand Tombal, from Université Catholique de Louvain, Louvain, Belgium, discusses the practice-changing and clinically relevant findings in prostate cancer that were presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium.

First he addresses a study on an artificial intelligence–driven biomarker to predict the benefit of androgen deprivation therapy in patients with localized disease. The results were far better than those of previous models for patient selection.

Next, he discusses two studies in advanced prostate cancer that look at the combination of a PARP inhibitor with abiraterone: PROpel, with olaparib; and MAGNITUDE, with niraparib. Both combinations were effective but in the latter study, benefit was seen only in patients with BRCA1/2 mutated disease.

Prof Tombal finishes with two abstracts that answer key clinical questions in advanced prostate cancer management: Should enzalutamide be continued in patients who are not progressing? Does triplet therapy improve survival in hormone-naive metastatic prostate cancer?


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.